Last reviewed · How we verify
GB491 combined with Letrozole
GB491 combined with Letrozole works by inhibiting a molecular target (likely CDK4/6 or similar cell-cycle regulator) to arrest tumor cell proliferation, while Letrozole blocks aromatase to reduce estrogen production in hormone receptor-positive breast cancer.
GB491 combined with Letrozole works by inhibiting a molecular target (likely CDK4/6 or similar cell-cycle regulator) to arrest tumor cell proliferation, while Letrozole blocks aromatase to reduce estrogen production in hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer (presumed, based on Letrozole pairing).
At a glance
| Generic name | GB491 combined with Letrozole |
|---|---|
| Sponsor | Genor Biopharma Co., Ltd. |
| Drug class | CDK4/6 inhibitor (presumed) combined with aromatase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GB491 is an investigational agent being studied in combination with Letrozole, an aromatase inhibitor used in estrogen receptor-positive breast cancer. The combination approach targets both cell-cycle progression and hormonal signaling to enhance anti-tumor efficacy. This dual mechanism aims to overcome resistance and improve outcomes in hormone-sensitive breast malignancies.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer (presumed, based on Letrozole pairing)
Common side effects
- Neutropenia
- Fatigue
- Nausea
- Arthralgia
Key clinical trials
- A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (PHASE3)
- A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB491 combined with Letrozole CI brief — competitive landscape report
- GB491 combined with Letrozole updates RSS · CI watch RSS
- Genor Biopharma Co., Ltd. portfolio CI